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Abstracts / Biol Blood Marrow Transplant 19 (2013) S257eS278 S277Result: During the course of this merger, we concluded that
only one cGMP policy was required since GMP users had
their own program SOP. However, GMP users would be
trained in QM policies besides their own P/P. Our current
SOPM has 70 P/P, 81 forms & 3 presentations, covering all
areas of processing and is compliant with R/AA.
Conclusion: Our rationale for standardizing SOPM is based
speciﬁcally on 21 CFR Part 1271 which governs all CPLs and is
mandatory law. With standardization, we will have clarity,
identical training for staff, and assurance of adherence to
similar methodology as required by law, resulting in
consistency, uniformity, legitimacy and safety in our labo-
ratory manufactured products.P/P Title Sub Titles Forms
I. Q M
1. Quality Assurance Organization; Terminology
2. Good Manufacturing
3. Responsibilities Lab Tech to MD
4. Security & Safety Safety manual etc 2
5. Utility Mgmt Air Handling; Compressor; etc 12
6. Training Training; Competency; CE 2
7. S.O.P. Mgmt Writing; Controls 5
8. Systems Controls; Validation 5
9. Event Mgmt 2
10. Audit 1
11. Equipment Mgmt BSC; Incubator etc; PM etc 7
12. Accreditation Mgmt 5
13. Supplies 2
14. E M Mgmt 4
15. Cleaning, Sanitization 2
16. Data Mgmt Documentation; Billing
II. Processing
1. HCT/P Quality Assurance Donor, Patient, Product 3
2. Quality Testing 1
3. Chain of Custody 3
4. HCT/P Manufacturing From Receipt to Infusion 20
5. Data Mgmt
6. Equipment Ops Cobe 2991; Cell Counter etc 5
III. cGMP
1. Gowning334
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Medicaid is a jointly funded federal-state program that
provides payment for health services for pregnant women,
children, parents, seniors and disabled individuals. States
establish and administer their own Medicaid programs and
determine the type, amount, and scope of services within
federal guidelines which mandate coverage of certain
beneﬁts. Optional beneﬁts that can be provided by the state
can lead to a wide variation of beneﬁts offered. Hemato-
poietic cell transplant (HCT) is not a mandatory covered
service for adults, and each state has the discretion to
choose whether to cover it and the extent of the coverage.
Variation in state policies can impact access to care for
patients. At the same time, many patients rely on Medicaid
for HCT coverage e according to HCUPnet data, Medicaid
paid for 3,064 HCT hospitalizations (16% of HCT discharges)
in the US in 2010. A national comparison of Medicaid
coverage for HCT was undertaken to learn more about statevariation. Information on HCT coverage beneﬁts for 2012
was collected from state Medicaid websites and was
compared to the recommendations for minimum beneﬁts
that have been developed by the National Marrow Donor
Program in collaboration with physicians, transplant
centers and payors (www.marrow.org/payor). Data was
coded on a three point scale depending on whether indi-
vidual state coverage met minimum beneﬁts criteria (score
2), provided some but not minimum beneﬁts (score 1), or
did not provide any beneﬁts (score 0) for the following 5
categories: 1) transplant procedure and disease indications,
2) donor search, 3) medications, 4) clinical trials, and 5)
patient food, lodging and transportation. Data were avail-
able for 47 states (Figure 1). No state provided minimum
coverage beneﬁts in all 5 categories and only three states
met the minimum in 4/5 categories. Our study highlights
substantial variation in Medicaid coverage by state for HCT
which may serve as a barrier to access to HCT for some
patients. In light of the Affordable Care Act and the deter-
mination of Essential Beneﬁts by individual states,
a common framework for complex medical procedures
such as HCT may be beneﬁcial.
Figure 1.
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The Beneﬁts of Metadata Analysis and Form Question
Harmonization
Sandra Sorensen, Robinette Renner. CIBMTR - IT, National
Marrow Donor Program, Minneapolis, MN
Background: In order to collect high-quality data from
multiple organizations, there must be a clear understanding
as to what data is needed and how it is to be reported.
Metadata, often described as “data about data,” describes
the content, quality, and other attributes of the data being
collected. These attributes include maximum length,
number of decimal places, data type (character, number, or
date), multiple choice answer vs. free text, etc. Historically,
FormsNet (FN), the Center for International Blood and
Transplant Research's (CIBMTR) electronic data capture
system, stored the metadata at the question level. Since
data collection forms were created independently, differ-
ences in question design and metadata became problem-
atic. For example, primary disease is a list of valid values on
one form and free text on another. In an effort to improve
data quality and facilitate analysis, the use of well-deﬁned
metadata and data standards, took on a more prominent
role.
Methods: Common data elements (CDE) were created using
the National Cancer Institute's Cancer Data Standards
